Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals
Authors:
- Collaborative Group for Studies of Yellow Fever VaccineCVCollaborative Group for Studies of Yellow Fever Vaccine
- Carla Rezende Barbosa BoninCBCarla Rezende Barbosa Bonin
- Guilherme Côrtes FernandesGFGuilherme Côrtes Fernandes
- Luiz Antonio Bastos CamachoLCLuiz Antonio Bastos Camacho
- Andréa Teixeira-CarvalhoATAndréa Teixeira-Carvalho
- Licia Maria Henrique da MotaLMLicia Maria Henrique da Mota
- Sheila Maria Barbosa de LimaSLSheila Maria Barbosa de Lima
- Ana Carolina Campi-AzevedoACAna Carolina Campi-Azevedo
- Olindo Assis Martins-FilhoOMOlindo Assis Martins-Filho
- Rodrigo Weber dos SantosRSRodrigo Weber dos Santos
- Marcelo LoboscoMLMarcelo Lobosco
Open Access
- 14 December 2020
- journal article
- conference paper
- Published by Springer Nature in BMC Bioinformatics
- Vol. 21 (S17) , 1-25
Abstract
Background: An effective yellow fever (YF) vaccine has been available since 1937. Nevertheless, questions regarding its use remain poorly understood, such as the ideal dose to confer immunity against the disease, the need for a booster dose, the optimal immunisation schedule for immunocompetent, immunosuppressed, and pediatric populations, among other issues. This work aims to demonstrate that computational tools can be used to simulate different scenarios regarding YF vaccination and the immune response of individuals to this vaccine, thus assisting the response of some of these open questions. Results: This work presents the computational results obtained by a mathematical model of the human immune response to vaccination against YF. Five scenarios were simulated: primovaccination in adults and children, booster dose in adult individuals, vaccination of individuals with autoimmune diseases under immunomodulatory therapy, and the immune response to different vaccine doses. Where data were available, the model was able to quantitatively replicate the levels of antibodies obtained experimentally. In addition, for those scenarios where data were not available, it was possible to qualitatively reproduce the immune response behaviours described in the literature. Conclusions: Our simulations show that the minimum dose to confer immunity against YF is half of the reference dose. The results also suggest that immunological immaturity in children limits the induction and persistence of long-lived plasma cells are related to the antibody decay observed experimentally. Finally, the decay observed in the antibody level after ten years suggests that a booster dose is necessary to keep immunity against YF.Keywords
Funding Information
- CNPq
- CAPES
- FAPEMIG
- UFJF
This publication has 30 references indexed in Scilit:
- A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malariaInternational Journal of Biological Macromolecules, 2020
- Epitope-based vaccine design: a comprehensive overview of bioinformatics approachesDrug Discovery Today, 2020
- Identification of potential therapeutic targets in Neisseria gonorrhoeae by an in-silico approachJournal of Theoretical Biology, 2020
- Predicting the artificial immunity induced by RUTI® vaccine against tuberculosis using universal immune system simulator (UISS)BMC Bioinformatics, 2019
- Development of Rift Valley fever (RVF) vaccine by genetic joining of the RVF-glycoprotein Gn with the strong adjuvant subunit B of cholera toxin (CTB) and expression in bacterial systemSaudi Journal of Biological Sciences, 2019
- A qualitatively validated mathematical-computational model of the immune response to the yellow fever vaccineBMC Immunology, 2018
- Vaccine Immunology2018
- 17DD yellow fever vaccineHuman Vaccines & Immunotherapeutics, 2013
- Applying computational modeling to drug discovery and developmentDrug Discovery Today, 2006
- From genome to vaccine: in silico predictions, ex vivo verificationVaccine, 2001